EAM
ZNTL icon

Eventide Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Eventide Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,475,054
Closed -$13.6M – 257
2024
Q4 		$13.6M Sell
4,475,054
-4,072,842
-48% -$13.3M 0.25% 118
2024
Q3 		$31.5M Hold
8,547,896
– – 0.54% 64
2024
Q2 		$35M Sell
8,547,896
-3,026,925
-26% -$33.8M 0.6% 56
2024
Q1 		$182M Buy
11,574,821
+14,846
+0.1% +$204K 2.86% 2
2023
Q4 		$175M Buy
11,559,975
+3,745,936
+48% +$54.7M 2.86% 3
2023
Q3 		$157M Buy
7,814,039
+936,236
+14% +$23.8M 2.82% 4
2023
Q2 		$194M Buy
6,877,803
+3,650,803
+113% +$87.6M 3.28% 1
2023
Q1 		$55.5M Buy
3,227,000
+1,070,485
+50% +$21.7M 1.02% 32
2022
Q4 		$43.4M Buy
2,156,515
+295,515
+16% +$6.36M 0.86% 41
2022
Q3 		$40.3M Buy
1,861,000
+857,000
+85% +$23.4M 0.79% 49
2022
Q2 		$28.2M Buy
1,004,000
+243,000
+32% +$6.44M 0.6% 58
2022
Q1 		$35.1M Buy
761,000
+232,000
+44% +$12.5M 0.55% 60
2021
Q4 		$44.5M Hold
529,000
– – 0.57% 60
2021
Q3 		$35.3M Buy
529,000
+108,600
+26% +$6.26M 0.46% 71
2021
Q2 		$22.4M Sell
420,400
-411,600
-49% -$22M 0.3% 89
2021
Q1 		$36.1M Hold
832,000
– – 0.54% 69
2020
Q4 		$43.2M Sell
832,000
-79,416
-9% -$3.58M 0.66% 55
2020
Q3 		$28.8M Sell
911,416
-3,289
-0.4% -$115K 0.56% 60
2020
Q2 		$42.5M Buy
+914,705
New +$35.1M 0.92% 39

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eventide Asset Management's ZNTL Position: Q1 2025 in Review

Eventide Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 4,475,054 shares — an estimated $13.6M sold.

Eventide Asset Management first reported a position in ZNTL in Q2 2020 and held it in 19 quarters. The position peaked at $194M in Q2 2023. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Eventide Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Eventide Asset Management sold 4,475,054 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $13.6M.
  • Eventide Asset Management first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 19 quarters.
  • Eventide Asset Management's Zentalis Pharmaceuticals position peaked at $194M in Q2 2023.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Eventide Asset Management's 13F filing for Q1 2025, filed 15 May 2025.